Bedaquiline practice in treatment of extensively drug-resistant mycobacterium tuberculosis in children: Clinical cases
Background. Bedaquiline is currently a drug of choice in therapy for extensively and multidrug-resistant tuberculosis. It is indicated for children from a 6-year age and young adults as part of a combination chemotherapy, in compliance with the medical council’s (MC) regulation on active extensively...
Main Authors: | A. A. Akzhigitova, T. N. Ignatova, A. К. Konratov, M. В. Теn |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Ministry of Healthcare of the Russian Federation. “Kuban State Medical University”
2022-05-01
|
Series: | Кубанский научный медицинский вестник |
Subjects: | |
Online Access: | https://ksma.elpub.ru/jour/article/view/2764 |
Similar Items
-
Bedaquiline in the treatment of extensively drugresistant tuberculosis
by: T. I. Morozova, et al.
Published: (2022-04-01) -
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
by: Francesco Pecora, et al.
Published: (2021-05-01) -
Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis
by: Camus Nimmo, et al.
Published: (2024-02-01) -
Efficacy and safety of regimen containing bedaquiline in children with drug-resistant tuberculosis
by: V. A. Aksenova, et al.
Published: (2021-10-01) -
The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data
by: Shanshan Li, et al.
Published: (2024-01-01)